Xilio Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 76.4 million compared to USD 88.22 million a year ago. Basic loss per share from continuing operations was USD 2.78 compared to USD 3.22 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 USD | +9.65% | +11.61% | +127.27% |
May. 14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+127.27% | 46.13M | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.62% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023